Harpoon Therapeutics, Inc.
- Jurisdiction
United States - LEI
549300VFZL0TEVXILA36 - ISIN
US41358P2056 (HARP )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
1
/ 7
Profile
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. Read full profile
Fundamentals
- Net revenue
€31.85M - Gross margin
92.5% - EBIT
-€33.37M - EBIT margin
-104.8% - Net income
-€26.33M - Net margin
-82.7%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: March 10, 2021 (Q4 2020)